Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DWIGHT DENMAN BLAKE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1811938814
CMS profile
173473
Location
UNION CITY, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$369.25

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $369.25 3

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $369.25 3

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DWIGHT DENMAN BLAKE

NPI 1811938814 · CMS profile ID 173473

Allopathic & Osteopathic Physicians / Internal Medicine

UNION CITY, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1811938814?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DWIGHT DENMAN BLAKE, NPI 1811938814, CMS profile ID 173473. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811938814?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). DWIGHT DENMAN BLAKE, NPI 1811938814, CMS profile ID 173473. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811938814?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
DWIGHT DENMAN BLAKE, NPI 1811938814, CMS profile ID 173473, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1811938814?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $369.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $122.4609/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206226406 CMS
AstraZeneca Pharmaceuticals LP $123.6708/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206781539 CMS
AstraZeneca Pharmaceuticals LP $123.1203/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206548933 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,138.93 6
PY2020 $1,159.49 24
PY2021 $122.45 1
PY2022 $473.01 5
PY2024 $1,818.96 5
PY2025 $369.25 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,386,564.75 80
PY2024 Recipient $57,732.20 4
PY2024 Principal investigator $2,455,115.26 49
PY2023 Recipient $2,277.99 4
PY2023 Principal investigator $2,791,306.83 51
PY2022 Recipient $92,276.00 3
PY2022 Principal investigator $3,022,384.19 43
PY2021 Recipient $6,646.99 2
PY2021 Principal investigator $1,337,039.14 22
PY2020 Recipient $1,658.45 3
PY2020 Principal investigator $145,341.90 6
PY2019 Recipient $24,425.96 3
PY2019 Principal investigator $177,128.41 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

55 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,110.75 12/31/2023 Non-covered Recipient Entity
ROPHE ADULT AND PEDIATRIC MEDICINE
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 998413053
Principal investigator 1 PFIZER INC. $7,537.40 12/22/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046174365
Principal investigator 1 PFIZER INC. $92,550.20 12/21/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046178811
Principal investigator 1 ABBVIE INC. $1,257.60 12/04/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 998409331
Principal investigator 1 Eli Lilly and Company $325,907.00 11/13/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1038135019
Principal investigator 1 ABBVIE INC. $450.00 11/08/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 998407073
Principal investigator 1 PFIZER INC. $73,815.00 10/25/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046263497
Principal investigator 1 Eli Lilly and Company $48,648.00 10/16/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1038146269
Principal investigator 1 PFIZER INC. $2,921.80 10/12/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046214285
Principal investigator 1 Eli Lilly and Company $5,750.00 10/06/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) No dispute reported 06/30/2026 1038152557
Principal investigator 1 ABBVIE INC. $2,138.52 10/04/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 998401985
Principal investigator 1 PFIZER INC. $13,331.50 09/23/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046188705
Principal investigator 1 PFIZER INC. $403.92 09/15/2023 Non-covered Recipient Entity
Rophe Adult and Pediatric Medicine
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046192893
Principal investigator 1 PFIZER INC. $403.92 09/06/2023 Non-covered Recipient Entity
Rophe Adult and Pediatric Medicine
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046235673
Principal investigator 1 ABBVIE INC. $4,488.62 09/05/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 998398301
Principal investigator 1 Eli Lilly and Company $294,652.00 09/01/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) No dispute reported 06/30/2026 1038146251
Principal investigator 1 PFIZER INC. $2,425.00 08/30/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332 NIRMATRELVIRRITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE No dispute reported 06/30/2026 1046251841
Principal investigator 1 Eli Lilly and Company $5,300.54 08/25/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1038133045
Recipient Eli Lilly and Company $600.01 08/24/2023 Covered Recipient Physician A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1038049657
Principal investigator 1 PFIZER INC. $1,785.00 08/24/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1045974853
Principal investigator 1 Eli Lilly and Company $860.06 08/22/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1038134073
Principal investigator 1 PFIZER INC. $8,688.40 08/22/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045936733
Principal investigator 1 ABBVIE INC. $535.34 08/09/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 998394273
Principal investigator 1 PFIZER INC. $1,944.60 08/09/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046031631
Principal investigator 1 PFIZER INC. $16,205.00 06/29/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046127481
Principal investigator 1 PFIZER INC. $16,853.20 06/22/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045986567
Recipient Eli Lilly and Company $730.01 06/20/2023 Covered Recipient Physician A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) No dispute reported 06/30/2026 1038049861
Principal investigator 1 PFIZER INC. $11,667.60 06/16/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046187881
Principal investigator 1 PFIZER INC. $18,149.60 06/14/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046324475
Principal investigator 1 Eli Lilly and Company $2,870.36 06/13/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) No dispute reported 06/30/2026 1038141063
Principal investigator 1 PFIZER INC. $16,212.00 06/09/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046044459
Principal investigator 1 PFIZER INC. $7,130.20 06/03/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046070621
Principal investigator 1 Eli Lilly and Company $117,609.00 05/26/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1038146225
Principal investigator 1 Eli Lilly and Company $727,998.00 05/26/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3B RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED TO SEMAGLUTIDE 2.4 MG IN ADULTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (SURMOUNT-5) No dispute reported 06/30/2026 1038152525
Principal investigator 1 PFIZER INC. $8,426.60 05/25/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046312437
Principal investigator 1 PFIZER INC. $8,426.60 05/16/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046131532
Principal investigator 1 PFIZER INC. $648.20 05/10/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045986553
Principal investigator 1 Eli Lilly and Company $103,322.00 04/18/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) No dispute reported 06/30/2026 1038134019
Recipient Eli Lilly and Company $650.01 04/09/2023 Covered Recipient Physician A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1038049867
Principal investigator 1 Eli Lilly and Company $3,754.73 04/04/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1038130891
Principal investigator 1 Eli Lilly and Company $3,890.83 03/27/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3B RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED TO SEMAGLUTIDE 2.4 MG IN ADULTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (SURMOUNT-5) No dispute reported 06/30/2026 1038140997
Principal investigator 1 PFIZER INC. $2,133.60 03/09/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046044445
Principal investigator 1 PFIZER INC. $97,371.40 03/04/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046087329
Principal investigator 1 PFIZER INC. $76,749.40 02/10/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046292817
Principal investigator 1 ABBVIE INC. $2,500.00 02/02/2023 Non-covered Recipient Entity
ROPHE ADULT AND PEDIATRIC MEDICINE
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) No dispute reported 06/30/2026 998367959
Recipient Eli Lilly and Company $297.96 01/31/2023 Covered Recipient Physician EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) No dispute reported 06/30/2026 1038049651
Principal investigator 1 Eli Lilly and Company $226.95 01/26/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 1038146207
Principal investigator 1 Eli Lilly and Company $13,060.96 01/24/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3 PARALLEL-DESIGN OPEN-LABEL RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1038134051
Principal investigator 1 Eli Lilly and Company $2,648.77 01/19/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) No dispute reported 06/30/2026 1038152499
Principal investigator 1 Eli Lilly and Company $39,726.00 01/13/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS No dispute reported 06/30/2026 1038152511
Principal investigator 1 PFIZER INC. $19,566.40 01/12/2023 Non-covered Recipient Entity
SKY Clinical Research Network Group
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046099693
Principal investigator 1 Eli Lilly and Company $1,787.26 01/10/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1038134953
Principal investigator 1 Eli Lilly and Company $193,445.00 01/03/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) No dispute reported 06/30/2026 1038130881
Principal investigator 1 Eli Lilly and Company $227,067.00 01/03/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3 PARALLEL-DESIGN OPEN-LABEL RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1038141009
Principal investigator 1 Eli Lilly and Company $154,955.00 01/03/2023 Non-covered Recipient Entity
SKY CLINICAL RESEARCH NETWORK GROUP
A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1038141925